NewLink Genetics to Present Data at the American Society of Clinical Oncology and Digestive Disease Week Annual Meetings

AMES, Iowa, April 11, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from its HyperAcute® Pancreas immunotherapy and its HyperAcute® Lung immunotherapy as well as its D-1MT IDO pathway inhibitor will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. In addition, data from its HyperAcute® Pancreas immunotherapy will be presented at the Digestive Disease Week (DDW) 2012 Annual meeting being held May 19-22, 2012 in San Diego, CA. A summary of the company’s ASCO and DDW poster presentations is follows:

MORE ON THIS TOPIC